Dr Vassiliki Papadimitrakopoulou speaks with ecancer at ESMO 2018 in Munich about her abstract for metastatic NSCLC regarding the IMpower-132 trial.
She gives a brief outline of the trial design and preliminary results, as well as information about subgroup analyses from the study.
These results are also discussed by Dr Fabrice Barlesi, here.
ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.